Biocon was ahead of the curve in anticipating the critical need for affordable therapy for chronic diseases in India and other emerging markets. We deftly balanced innovation and affordability with an intent to bring cost-effective biologics, including proprietary molecules, and differentiated small molecule formulations for chronic conditions to patients.

Biocon Biologics’ Branded Formulations India business is making an impact in the country through its wide portfolio that includes biologics (including biosimilars, novel molecules, and others), in-licensed products, and branded generics for acute and chronic conditions. The business has a large field force network focusing on specialty brands in critical therapies and offering world-class quality therapeutics to thousands of patients in India. The portfolio spans therapeutic areas such as metabolics (diabetes, cardiovascular), oncology, nephrology, autoimmune diseases and critical care.

The Branded Formulations India team was instrumental in helping more than 50,000 COVID-19 patients through distribution of a comprehensive Covid-care portfolio in FY22.

The Branded Formulations business has been a strong value builder for Biocon Biologics, having created considerable brand equity with doctors and patients over the years through its affordable and differentiated portfolio in challenging disease spaces.

A combination of products as well as patient and physician support programs have enabled Biocon Biologics to be a strong player in India’s biopharmaceuticals market.